Skip to main content

Table 1 Activity of PD-1-pathway-targeted agents in patients with advanced Merkel cell carcinoma

From: Immunotherapy for Merkel cell carcinoma: a turning point in patient care

Drug name Drug class N Number of prior systemic therapies ORR (%) Reference
Avelumab Anti-PD-L1 88 1–4 33 [40]
29 0 65 [53]
Nivolumab Anti-PD-1 15 0 73* [44]
10 1–2 50*
Pembrolizumab Anti-PD-1 26 0 56 [35]
  1. *RECIST v1.1, investigator assessed